Current Diabetes Reports

, Volume 13, Issue 4, pp 500–508

New and Developing Drugs for the Treatment of Neuropathic Pain in Diabetes

Microvascular Complications-Neuropathy (D Ziegler, Section Editor)

DOI: 10.1007/s11892-013-0396-6

Cite this article as:
Freeman, R. Curr Diab Rep (2013) 13: 500. doi:10.1007/s11892-013-0396-6


A number of agents from diverse pharmacological classes are used to treat neuropathic pain associated with diabetic peripheral neuropathy. Only three of these have regulatory approval for this indication in the U.S. In this focused article, I will discuss selected drugs, newly approved or in development, to treat neuropathic pain in patients with diabetic neuropathy. These will include agonists and antagonists of the transient receptor potential channels, a family of receptor proteins that play a role in the transduction of physical stress; sodium channel isoform specific antagonists; a recently approved dual-action opioid receptor agonist–norepinephrine reuptake inhibitor; gene therapy for neuropathic pain; and anti-nerve growth factor molecules. Mechanisms of action, preclinical supporting data, clinical trial evidence, and adverse effects will be reviewed.


Neuropathic painDiabetic peripheral neuropathyTRPV1TRPA1capsaicinSodium channel antagonistsNaV1.7Anti-NGF antibodiesGene therapyTapentadolDiabetes

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Center for Autonomic and Peripheral Nerve DisordersBeth Israel Deaconess Medical CenterBostonUSA